1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. EQT AB (publ)
  6. News
  7. Summary
    EQT   SE0012853455

EQT AB (PUBL)

(EQT)
  Report
Delayed Nasdaq Stockholm  -  11:29 2022-07-01 am EDT
213.90 SEK   +2.15%
06/30Invitation to presentation of EQT AB's Half-year Report 2022
AQ
06/29EQT-backed Singaporean Healthcare Provider Mulls Selling Minority Stake
MT
06/28European Commission Approves EQT, HgCapital, TA Associates' Acquisition of IFS
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EQT's Galderma announces positive trial results on skin drug

06/22/2022 | 02:00am EDT
FILE PHOTO: A Swiss flag is pictured on the Federal Palace in Bern

BERLIN, June 22 (Reuters) - EQT's Galderma on Wednesday said its injectable drug nemolizumab helped patients suffering from the rare skin disease prurigo nodularis in a trial, potentially underpinning the owner's ambitions to list the skincare firm.

In a late-stage trial, Galderma's drug was shown to remove lesions and ease itch in some patients. Itch is a chronic symptom of the potentially debilitating skin disease.

Sources told Reuters in May that EQT is delaying listing plans for Galderma as market volatility and recession fears in Europe cool investor appetite for what could be Switzerland's biggest flotation in more than two decades.

The listing could happen in the autumn or early next year depending on market conditions, the sources said at the time.

Japan's Maruho Co. Ltd is also working on a prurigo nodularis treatment while French drugmaker Sanofi is running trials to get its bestselling eczema drug Dupixent also approved for the disease. (Reporting by Ludwig Burger, Writing by Miranda Murray)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BANK OF AMERICA CORPORATION -0.08% 31.035 Delayed Quote.-30.03%
BNP PARIBAS -0.12% 45.31 Real-time Quote.-25.35%
CITIGROUP INC. 0.37% 46.03 Delayed Quote.-23.85%
CREDIT SUISSE GROUP AG 0.07% 5.424 Delayed Quote.-38.91%
EQT AB (PUBL) 2.15% 213.9 Delayed Quote.-57.53%
MORGAN STANLEY 0.03% 75.85 Delayed Quote.-22.51%
MSCI SINGAPORE (GDTR) -1.31% 5282.25 Real-time Quote.-14.75%
NOVARTIS AG -0.64% 80.33 Delayed Quote.0.71%
SANOFI 1.22% 97.52 Real-time Quote.8.76%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) 0.93% 54.6262 Delayed Quote.-30.64%
All news about EQT AB (PUBL)
06/30Invitation to presentation of EQT AB's Half-year Report 2022
AQ
06/29EQT-backed Singaporean Healthcare Provider Mulls Selling Minority Stake
MT
06/28European Commission Approves EQT, HgCapital, TA Associates' Acquisition of IFS
MT
06/28EQT Wins European Commission's Nod To Purchase BPEA
MT
06/23Correction to EQT Sells Facile.it Article
DJ
06/23EQT Sells Italian Online Price Comparison Platform Facile.it to Silver Lake
DJ
06/22EQT, Oakley Capital Sell Italian Price Comparison Platform to Silver Lake; Facile Becom..
MT
06/22EQT Private Equity to sell Facile.it, Italy's largest online price comparison platform,..
AQ
06/22EQT's Galderma Says Nemolizumab Benefits Rare Skin Disease Patients in Late-stage Trial
MT
06/22Sweden's EQT to Buy UK-based SPT Labtech for $795 MIllion
MT
More news
Analyst Recommendations on EQT AB (PUBL)
More recommendations
Financials
Sales 2021 1 461 M 1 528 M 1 528 M
Net income 2021 796 M 832 M 832 M
Net cash 2021 628 M 656 M 656 M
P/E ratio 2021 24,3x
Yield 2021 1,94%
Capitalization 19 456 M 20 339 M 20 339 M
EV / Sales 2021 12,9x
EV / Sales 2022 11,2x
Nbr of Employees 1 059
Free-Float 37,6%
Chart EQT AB (PUBL)
Duration : Period :
EQT AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EQT AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 19,55 €
Average target price 38,02 €
Spread / Average Target 94,5%
EPS Revisions
Managers and Directors
Christian Otto Sinding Chief Executive Officer & Managing Partner
Kim Henriksson Chief Financial Officer
Yngve Conni Jonsson Director
Caspar Mats Andreas Callerström Chief Operating Officer & Deputy CEO
Gordon Robert Halyburton Orr Independent Director
Sector and Competitors
1st jan.Capi. (M$)
EQT AB (PUBL)-57.53%20 339
PARTNERS GROUP HOLDING AG-42.31%24 125
PETERSHILL PARTNERS PLC-19.85%3 073
BRIDGEPOINT GROUP PLC-50.99%2 555
GOLUB CAPITAL BDC, INC.-16.00%2 217
RATOS AB (PUBL)-23.50%1 461